Subject index of volume 103

Abuse 233
Abuse potential 183
Acetaldehyde 74
Acetylcholine 343
ACTH 177
acute dystonia 503
Adenosine antagonists A_1 and A_2 541
Adrenalectomy 177
Adrenals 339
β-Adrenoceptors 204, 357
α_2-Adrenoceptors 251
β-Adrenoceptor 351
α_1-Adrenoceptor 28
AF64A 215
Aging 41, 143, 265
Akathisia 138
Alaproclate 567
Alpha-methyl-para-tyrosine 74
Amnesia 545
Amphetamine 19, 62, 187, 197
Amphetamine psychosis 480
d-Amphetamine 50, 436
Amygdala 473
Analgesia 67, 177
Animal model 415
Anti-conflict 314
Anti-convulsion 314
Antidepressant 330
Antidepressant activity 524
Antidepressant drugs 251
Antidepressant treatment 357
Antidepressants 204, 297, 306
Antipsychotic drugs 150, 443
Antipsychotics 323
Anxiety 227, 449, 541, 551
Anxiogenesis 473
Anxiogenics 415
Anxiolysis 473
Anxiolytic effect 91
Anxiolytics 154, 415, 529
Apomorphine 19, 78
Asrecoline 215
Avoidance 115
Awakening 28
A−69024 209
A_2 receptors 78

Baboons 154
Barbiturates 154
Behavior 50, 67
Behavioral tolerance 115, 121, 268
Benzodiazepine 56, 233, 545
Benzodiazepines 154, 529
Brain regions 339
Brotizolam 166
BUBU 493

Caloric intake 103
Cannabinoid 115
Cannabis 277
Carbon monoxide 223
Cerebrospinal fluid 287
CGS15943A 541
Chlordiazepoxide 473
p-Chlorophenylalanine 351
Choline 343
Cholinergic manipulation 503
Cholinergic neurotoxin 215
Chronic drug administration 204
Clonazepam 110
Clonidine 268
Clonidine-induced hypoactivity 251
Clonidine-induced mydriasis 251
Clozapine 323
Cocaine 33, 50, 62, 297, 306, 455
Conditioned place aversion 99
Conditioned place preference 99, 271
Conditioned reinforcement 187, 197
Conditioned taste aversion 74
Conflict behavior 455
Core temperature 291
Corticosterone 425
Corticotropin-releasing factor 227, 330
Cortisol 258
Cyprodime 380
Cytidine 1

DAGO 493
Defence 449
Defense 56
Delta opioid receptor antagonist 467
Dependence 233
Depression 480
Development 388, 398
Diazepam 436, 455, 513, 545
Diazepam binding inhibitor 339
Dissociative anesthetics 462
DN−2327 314
Dopamine 78, 95, 187, 271, 323, 343, 480
Dopamine antagonists 99
Dopamine D1 receptor 41
Dopamine receptor antagonist 150
Dopamine receptors 6
Dopaminergic antagonist 33
Dorsal periaqueductal grey 91
Dorsal raphe 357
Dorsal raphe nucleus 524
DPCPX 541
DRL 121
Drug abuse 154, 436
Drug discrimination 50, 67, 166
Drug reward 455
DSTBULET 493
Dyskinesia 462
D−1 receptor 209
D−1 receptors 503
D2 dopamine receptors 449
D−2 receptors 503
D_1-dopamine receptors 150

Early protein malnutrition 513
EEG 375
EEG slowing 567
Electroconvulsive shock 251, 343
Electroshock seizure threshold 380
Elevated plus-maze 91, 227, 513
Enkephalinase inhibitors 467
Enkephalins 467
Ethanol 74, 110, 227, 425
Ethanol-stimulated activity 557
Ethopharmacology 56
Excitatory amino acids 91
Extrapyramidal side-effects 280
Extrasynaptic receptors 366
E−10-hydroxynortriptyline 287

Familiar novel, fear inducing environment 493
FAST and SLOW mice 557
Feeding 171, 366
Fixed interval 115
Fixed ratio 115
Flerobuterol 357
Flumazenil 110, 384, 519
Flurothyl 343
FR 121
Free swim behavior 240
Frontal cortex 41

$GABA_B$ receptors 204
Gastric damage 110
Genetic differences 244
Genetic selection 467
Growth hormone 140

Haloperidol 244
Heritability 557
High voltage spindles 265
Hippocampus 357
HMPG 287
Homovanillic acid 95
Homovanillic aicd (HVA) 551
Hormone 443
HPLC assay 384
5-HT 291, 513
5-HT_{1A} agonists 529
5-HT_{1A} receptor 140
5-HT_{1C}/5-HT_2 receptors 258
Human 223, 277
Human drug discrimination 436
Hunger 103
HVS 567
5-Hydroxyindoleacetic acid (5−HIAA) 551
5-Hydroxytryptophan 258, 351
Hypophysectomy 177
Hypothalamic paraventricular nucleus 366

ICI−204,636 323
Indomethacin 95
Intake-habits 233
Intoxication 277
Intracerebral injection 91
Iodinated radioligand 6
Ipsapirone 529
Iron 138
Isobutylmethylxanthine 388, 398
Isoprenalineinduced drinking 351

Kappa opioid 129
Ketamine 462

Lateralization 19
Learning 388
Linguopharyngeal events 462
Local injection VTA 493
Locomotion 297, 306, 541
Locomotor activity 204, 425
Locus coeruleus 330

Lorazepam 83
LY171666 271

Marijuana 223
Memory 83, 143, 519
Memory retention 215
Mesolimbic system 209
Methadone maintenance 538
3-Methoxy-4-hydroxy-phenylgycol (MHPG) 551
Methylphenidate 436
Methysergide 567
Mianserin 330, 388, 398
Mice 244, 297, 306, 380
Microdialysis 343
Midazolam 519, 545
MK-801 462
Modafinil 28
Monkey brain 150
Monoamines 143
Morphine 67, 115, 129, 183, 407
Morphine withdrawal 398
Motor activity 62
Mu opioid 129
Multi-infarct dementia 1
Muscle relaxation 314
M_1 and M_2 receptors 162

N. accumbens 209
Naloxone 172, 177, 407
Naloxone sensitivity 129
Naltrexone 67, 425
Naltrindole 380
/-Nantradol 115
NCQ 298 6
Neuroleptic 244
Neuroleptic drugs 138
Neuroleptics 46
Neuropeptides 197
Neuropsychological tests 545
Nicotine 62, 103
NMDA antagonism 462
NMDA receptor antagonist 91
Nocturnal activity 28
Non-benzodiazepine anxiolytics 513
Non-response 244
Nonsmokers 103
Noradrenergic 330
Norbinaltorphimine 380
Norepinephrine 480
Nucleus accumbens 187, 197, 271

8-OH–DPAT–PCPA 99
8-OH-DPAT 291, 524
Ondansetron 567
Opioid tolerance 129
Opioids 172, 467
Oxotremorine 215

Paracrine transmission 366
Parkinsonism drugs 162
Passive avoidance learning 215
Peer-rearing 551
Pentobarbital 166
Pentobarbital potentiation 314
Peptidases inhibitor kelatorphan 493
Pharmacokinetics 46, 287, 384
Phencyclidine 121
Physostigmine 215, 240
Pilocarpine 567
Pindolol 140
Pirenzepine 162
Place conditioning 183, 209
Plasma methadone concentrations 538
Plus maze test 449
Positron emission tomography 41, 150
Potential "atypical" neuroleptic 280
Prazosin 28
Pre-exposure 74
Prolactin 46, 140, 258, 443
Prostaglandin 95
Psychomotor impairment 519
Psychomotor performance 83
Psychomotor stimulant effects 33
Psychophysiology 538
Purposeless chewing 503
P300 1

Quipazine 351

Raphe nuclei 291
Rat 50, 56, 78, 115, 121, 177, 183, 187, 197, 209, 215, 291, 366, 384, 407, 415, 493, 513, 524
Rats 62, 67, 129, 240, 265, 268
REM sleep 375
Remoxipride 46, 443
Restraint-stress 425
Reward 187
Rhesus monkey 28
Rhesus monkeys 166, 551
Ritanserin 258
Ro 5–3663 110
Rotation 78

Salicylamide 6
Saliva 277
S(+)Aporphines 323
Savoxepine 280
Schedule-controlled behavior 129
Schizophrenia 95, 280
SCH23390 41, 209
Scopolamine 83, 240
Sedation 83, 519
Selection 244
Selective breeding 557
Selective opioid receptor antagonists 380
Self-administration 166, 455
Sensitization 62
Sensitization to drug reward 183
Septum 473
Serotonin 143, 297, 306, 357, 388, 398
Serotonin$_{1A}$ receptor 524
Sertraline 297, 306
Sex 551
Shock intensity 268
Sibutramine hydrochloride 251
Sidman avoidance 268
SKF38393 271
Sleep 375
Slow wave sleep 375
Smokers 103
Smoking 223
Smoking topography 223
Social interaction 449
SPECT 6
Spectral analysis 375
Spontaneous activity 493
Squirrel monkey 115
Stability 384
Stimulant drugs 480
Stimulant-induced anxiety 455
Stress 330, 339
Striatum 41, 78, 187, 343
Subjective effects 223
Submission 56
Sulpiride 443

Tail flick latency 407
Tardive dyskinesia 46
Taste conditioning 183
Tetrahydroaminoacridine 240, 265
Δ^9-tetrahydrocannabinol 172
THC 277
Δ^9-THC 172
Time-Delay 121
Trazodone 351
Tricyclic antidepressant 375
Tricyclic antidepressants 351
Tryptophan 140
Turning 19

Use 233

Ventral tegmental area 197
Vibrissae 19
Voluntary alcohol consumption 467

Withdrawal 227, 407, 529

Yohimbine 407